| Year |
Citation |
Score |
| 2022 |
Song PN, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S, Heinzman K, Lapi SE, Yang ES, Sorace AG. Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer. Cancers. 14. PMID 35205763 DOI: 10.3390/cancers14041015 |
0.303 |
|
| 2020 |
Zeng L, Boggs DH, Xing C, Zhang Z, Anderson JC, Wajapeyee N, Veale C, Bredel M, Shi LZ, Bonner JA, Willey CD, Yang ES. Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth. Frontiers in Genetics. 11: 1036. PMID 33133138 DOI: 10.3389/Fgene.2020.01036 |
0.393 |
|
| 2020 |
Bastola S, Pavlyukov MS, Yamashita D, Ghosh S, Cho H, Kagaya N, Zhang Z, Minata M, Lee Y, Sadahiro H, Yamaguchi S, Komarova S, Yang E, Markert J, Nabors LB, et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nature Communications. 11: 4660. PMID 32938908 DOI: 10.1038/S41467-020-18189-Y |
0.316 |
|
| 2020 |
Zeng L, Nikolaev A, Xing C, Della Manna DL, Yang ES. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics. PMID 32371584 DOI: 10.1158/1535-7163.Mct-19-0946 |
0.428 |
|
| 2020 |
McDonald AM, Spencer SA, Willey CD, Bonner JA, Dobelbower MC, Swain TA, Nabell L, McCammon S, Carroll WR, McGwin G, Bhatia S, Yang ES. Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 32350670 DOI: 10.1007/S00520-020-05474-1 |
0.32 |
|
| 2020 |
Doo DW, Meza-Perez S, Londoño AI, Goldsberry WN, Katre AA, Boone JD, Moore DJ, Hudson CT, Betella I, McCaw TR, Gangrade A, Bao R, Luke JJ, Yang ES, Birrer MJ, et al. Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. Therapeutic Advances in Medical Oncology. 12: 1758835920913798. PMID 32313567 DOI: 10.1177/1758835920913798 |
0.358 |
|
| 2020 |
Chandrashekar DS, Chakravarthi BVSK, Robinson AD, Anderson JC, Agarwal S, Balasubramanya SAH, Eich ML, Bajpai AK, Davuluri S, Guru MS, Guru AS, Naik G, Della Manna DL, Acharya KK, Carskadon S, ... ... Yang ES, et al. Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. Oncogene. PMID 32231273 DOI: 10.1038/S41388-020-1275-7 |
0.432 |
|
| 2020 |
McDonald AM, Yang ES, Saag KG, Levitan EB, Wright NC, Fiveash JB, Rais-Bahrami S, Bhatia S. Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study. Archives of Osteoporosis. 15: 32. PMID 32112196 DOI: 10.1007/S11657-020-0711-1 |
0.301 |
|
| 2020 |
Nair S, Trummell HQ, Rajbhandari R, Thudi NK, Nozell SE, Warram JM, Willey CD, Yang ES, Placzek WJ, Bonner JA, Bredel M. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer. Plos One. 15: e0229077. PMID 32069320 DOI: 10.1371/Journal.Pone.0229077 |
0.302 |
|
| 2020 |
Nikolaev A, Fiveash JB, Yang ES. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG. International Journal of Molecular Sciences. 21. PMID 31940975 DOI: 10.3390/Ijms21020490 |
0.375 |
|
| 2020 |
Kelly WK, Leiby B, Einstein DJ, Szmulewitz RZ, Sartor AO, Yang ES, Sonpavde G. Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo). Journal of Clinical Oncology. 38: 5540-5540. DOI: 10.1200/Jco.2020.38.15_Suppl.5540 |
0.33 |
|
| 2020 |
Ahn ER, Garrett-Mayer E, Halabi S, Mangat PK, Calfa CJ, Alva AS, Suhag VS, Hamid O, Dotan E, Yang ES, Alese OB, Yost KJ, Marr AS, Palmer MC, Thompson FL, et al. Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Journal of Clinical Oncology. 38: 4637-4637. DOI: 10.1200/Jco.2020.38.15_Suppl.4637 |
0.317 |
|
| 2020 |
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Marcom PK, Nanda R, Shah PD, Ballinger TJ, Yang ES, Melisko ME, Brufsky A, Vinayak S, Demeo M, Jenkins C, Domchek SM, et al. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). Journal of Clinical Oncology. 38: 1002-1002. DOI: 10.1200/Jco.2020.38.15_Suppl.1002 |
0.362 |
|
| 2019 |
Demark-Wahnefried W, Rogers LQ, Gibson JT, Harada S, Frugé AD, Oster RA, Grizzle WE, Norian LA, Yang ES, Della Manna D, Jones LW, Azrad M, Krontiras H. Randomized Trial of Weight Loss in Primary Breast Cancer: Impact on Body Composition, Circulating Biomarkers and Tumor Characteristics. International Journal of Cancer. PMID 31442303 DOI: 10.1002/Ijc.32637 |
0.359 |
|
| 2019 |
Willey CD, Anderson JC, Trummell HQ, Naji F, de Wijn R, Yang ES, Bredel M, Thudi NK, Bonner JA. Differential escape mechanisms in cetuximab-resistant head and neck cancer cells. Biochemical and Biophysical Research Communications. PMID 31311651 DOI: 10.1016/J.Bbrc.2019.06.159 |
0.307 |
|
| 2019 |
Lin VTG, Yang ES. The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology. Journal of the National Cancer Institute. PMID 31165154 DOI: 10.1093/Jnci/Djz114 |
0.37 |
|
| 2019 |
Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg RCAM, Yang ES, Bradner JE, Yoon KJ. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. Ebiomedicine. PMID 31126889 DOI: 10.1016/J.Ebiom.2019.05.035 |
0.343 |
|
| 2019 |
Beggs R, Yang ES. Targeting DNA repair in precision medicine. Advances in Protein Chemistry and Structural Biology. 115: 135-155. PMID 30798930 DOI: 10.1016/Bs.Apcsb.2018.10.005 |
0.33 |
|
| 2019 |
McDonald AM, Dobelbower MC, Yang ES, Clark GM, Jacob R, Kim RY, Cardan RA, Popple R, Nix JW, Rais-Bahrami S, Fiveash JB. Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial. Advances in Radiation Oncology. 4: 90-95. PMID 30706015 DOI: 10.1016/J.Adro.2018.09.007 |
0.306 |
|
| 2019 |
Matrana MR, Tomlins SA, Kwiatkowski K, Mitchell K, Suga JM, Dees EC, Burkard ME, Khatri J, Safa MM, Yang ES, Parsons B, Menter AR, Thompson MA, Gonzalez AO, Wassenaar TR, et al. No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment. Journal of Clinical Oncology. 37: 3073-3073. DOI: 10.1200/Jco.2019.37.15_Suppl.3073 |
0.326 |
|
| 2019 |
Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow J, Gray RJ, McShane LM, Rubenstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, et al. Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct139 |
0.356 |
|
| 2019 |
Nikolaev AY, Fiveash JB, Yang ES. Abstract 3920: Differential effects of Jumonji family demethylase and EZH2 H3K27 methyltransferase inhibition on radiation sensitivity of H3K27M mutant DIPG Cancer Research. 79: 3920-3920. DOI: 10.1158/1538-7445.Am2019-3920 |
0.353 |
|
| 2019 |
Nikolaev A, Zeng L, Bonner J, Yang E. Pharmacological Reactivation of Mutant p53 Sensitizes Tumor Cells to Radiation by Triggering Caspase-Independent Ferroptosis Pathway International Journal of Radiation Oncology*Biology*Physics. 105: S75. DOI: 10.1016/J.Ijrobp.2019.06.533 |
0.327 |
|
| 2019 |
Boggs H, Zeng L, Veale C, Wei S, Bonner J, Yang E. Combining PARP and DNA-PK Inhibitors with Irradiation Enhances Cytotoxicity in Human Head and Neck Cancer Cells International Journal of Radiation Oncology*Biology*Physics. 105: S162. DOI: 10.1016/J.Ijrobp.2019.06.181 |
0.415 |
|
| 2018 |
Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Michael Straughn J, Norian LA, Arend RC. The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer. PMID 30423192 DOI: 10.1002/Cncr.31761 |
0.376 |
|
| 2018 |
Lin VTG, Nabell LM, Spencer SA, Carroll WR, Harada S, Yang ES. First-Line Treatment of Widely Metastatic -Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1166-1170. PMID 30323086 DOI: 10.6004/Jnccn.2018.7056 |
0.363 |
|
| 2018 |
Coker MA, Dulaney C, McDonald A, Nix JW, Gordetsky JB, Yang ES, Dobelbower MC, Rais-Bahrami S. Stereotactic Radiosurgery for Prostate Cancer Following Magnetic Resonance Imaging Directed Biopsy: A Multidisciplinary Approach with Case Examples. Cureus. 10: e2524. PMID 29942727 DOI: 10.7759/Cureus.2524 |
0.347 |
|
| 2018 |
Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES. Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. Molecular Cancer Therapeutics. PMID 29592880 DOI: 10.1158/1535-7163.Mct-17-0302 |
0.427 |
|
| 2018 |
Arend RC, Londono AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM, Estes JM, Novak L, Crossman DK, et al. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research : McR. PMID 29523763 DOI: 10.1158/1541-7786.Mcr-17-0594 |
0.368 |
|
| 2018 |
Godwin JL, Hoffman-Censits JH, Den RB, Knudsen KE, Schiewer MJ, Leiby BE, Southwell T, Hubert C, Patnaik A, Sonpavde G, Sartor AO, Yang ES, Kelly WK. c15-162: Phase IB trial of radium 223 and niraparib in patients with castrate resistant prostate cancer (NiraRad). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps385 |
0.431 |
|
| 2018 |
Stringer-Reasor EM, Yang ES, May JE, Caterinicchia V, Li Y, Forero-Torres A. An open label, pilot study of veliparib (ABT-888) and lapatinib in patients with metastatic, triple negative (ER, PR, and HER-2 negative) breast cancer. Journal of Clinical Oncology. 36: 1095-1095. DOI: 10.1200/Jco.2018.36.15_Suppl.1095 |
0.349 |
|
| 2018 |
Alba Martinez A, Londono A, Shelton K, Montgomery A, Kim B, Katre A, Huh W, Yang E, Bevis K, Straughn J, Leath C, Arend R. Using gene expression and DNA mutations to predict recurrence in high-intermediate risk endometrial cancer Gynecologic Oncology. 149: 186. DOI: 10.1016/J.Ygyno.2018.04.423 |
0.348 |
|
| 2018 |
Nikolaev A, Zeng L, Spencer S, Bonner J, Yang E. A Computational Approach to Discovery of Novel Mutant p53 Reactivating Molecules As Targeted Radio-Sensitizing Agents for Head and Neck Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S185-S186. DOI: 10.1016/J.Ijrobp.2018.07.068 |
0.321 |
|
| 2017 |
Chakraborty A, Dorsett KA, Trummell HQ, Yang ES, Oliver PG, Bonner JA, Buchsbaum DJ, Bellis SL. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. The Journal of Biological Chemistry. PMID 29191829 DOI: 10.1074/Jbc.M117.808584 |
0.379 |
|
| 2017 |
Garcia PL, Miller AL, Gamblin TL, Council LN, Christein JD, Arnoletti JP, Heslin MJ, Reddy S, Richardson JH, Cui X, van Waardenburg RCAM, Bradner JE, Yang ES, Yoon KJ. JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma. Molecular Cancer Therapeutics. PMID 29142067 DOI: 10.1158/1535-7163.Mct-16-0922 |
0.385 |
|
| 2017 |
Dulaney CR, Rais-Bahrami S, Manna DD, Gordetsky JB, Nix JW, Yang ES. DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy. Oncotarget. 8: 68038-68046. PMID 28978094 DOI: 10.18632/Oncotarget.19145 |
0.397 |
|
| 2017 |
Nikolaev A, Yang ES. The Impact of DNA Repair Pathways in Cancer Biology and Therapy. Cancers. 9. PMID 28925933 DOI: 10.3390/Cancers9090126 |
0.399 |
|
| 2017 |
Demark-Wahnefried W, Rais-Bahrami S, Desmond RA, Gordetsky JB, Hunter GR, Yang ES, Azrad M, Frugé AD, Tsuruta Y, Norian LA, Segal R, Grizzle WE. Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer. British Journal of Cancer. PMID 28881355 DOI: 10.1038/Bjc.2017.303 |
0.329 |
|
| 2017 |
McDonald AM, Fiveash JB, Kirkland RS, Cardan RA, Jacob R, Kim RY, Dobelbower MC, Yang ES. Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancer. Urologic Oncology. PMID 28797587 DOI: 10.1016/J.Urolonc.2017.07.012 |
0.327 |
|
| 2017 |
Maia MC, Yang ES, Agarwal N, Pal SK. A step towards predicting checkpoint inhibitor response in kidney cancer. The Lancet. Oncology. 18: 982-983. PMID 28759367 DOI: 10.1016/S1470-2045(17)30533-8 |
0.334 |
|
| 2017 |
Rohrbach TD, Jones RB, Hicks PH, Weaver AN, Cooper TS, Eustace NJ, Yang ES, Jarboe JS, Anderson JC, Willey CD. MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines. Oncology Letters. 13: 1216-1222. PMID 28454237 DOI: 10.3892/Ol.2016.5550 |
0.363 |
|
| 2017 |
Yang ES, Willey CD, Mehta A, Crowley MR, Crossman DK, Chen D, Anderson JC, Naik G, Della Manna DL, Cooper TS, Sonpavde G. Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. Oncotarget. 8: 21710-21718. PMID 28423512 DOI: 10.18632/Oncotarget.15558 |
0.329 |
|
| 2017 |
Zeng L, Beggs RR, Cooper TS, Weaver AN, Yang ES. Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics. PMID 28138028 DOI: 10.1158/1535-7163.Mct-16-0352 |
0.402 |
|
| 2017 |
Dulaney C, Marcrom S, Stanley J, Yang ES. Poly(ADP-ribose) Polymerase Activity and Inhibition in Cancer. Seminars in Cell & Developmental Biology. PMID 28087320 DOI: 10.1016/J.Semcdb.2017.01.007 |
0.402 |
|
| 2017 |
Tawfik C, Kim B, Londono A, Katre AA, Della Manna DL, Huh WK, Yang ES, Bevis KS, Straughn JM, Leath CA, Arend RC. High-intermediate risk endometrial cancer: Can gene expression predict recurrence? Journal of Clinical Oncology. 35: 5591-5591. DOI: 10.1200/Jco.2017.35.15_Suppl.5591 |
0.358 |
|
| 2017 |
Wielgos M, Rajbhandari R, Nozell S, Wei S, Yang ES. Abstract B11: HER2 regulates PARP-1 expression via the let-7a microRNA in HER2+ breast cancer Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B11 |
0.364 |
|
| 2017 |
Weaver AN, Cooper TS, Manna DD, Wei S, Rosenthal EL, Yang ES. Abstract A32: Upregulation of the Notch signaling pathway is associated with mortality and in vitro cell invasion in squamous cell carcinoma of the oral cavity Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A32 |
0.375 |
|
| 2017 |
Yang ES, Wielgos M, Rajbhandari R, Wei S, Nozell S. Abstract 471: HER2 regulates PARP-1 expression by suppressing the let-7a microRNA in HER2+ breast cancer Cancer Research. 77: 471-471. DOI: 10.1158/1538-7445.Am2017-471 |
0.327 |
|
| 2017 |
Miller AL, Gamblin T, Waardenburg Rv, Yang E, Bradner J, Yoon K. Abstract 1075: JQ1 induces DNA damage, inhibits expression of DNA repair proteins, and synergizes with PARP inhibitors in pancreatic cancer cells Cancer Research. 77: 1075-1075. DOI: 10.1158/1538-7445.Am2017-1075 |
0.415 |
|
| 2017 |
Bonner J, Yang E, Trummell H, Nozell S, Willey C, Bredel M. Non-coding MIR491 is associated with less EGFr expression and greater radiosensitivity in human head and neck cancer cell lines Annals of Oncology. 28: x6. DOI: 10.1093/Annonc/Mdx652.020 |
0.307 |
|
| 2017 |
Yang ES, Zeng L, Beggs R, Cooper T, Weaver A. Oral Scientific SessionsCombining Chk1/2 Inhibition With Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.344 |
0.305 |
|
| 2017 |
Kirkland RS, Cardan RA, Fiveash JB, Yang ES, Dobelbower MC, Jacob R, Kim RY, McDonald A. Subcutaneous Adipose Tissue Characteristics and Risk of Biochemical Recurrence in Men with High Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1194 |
0.31 |
|
| 2016 |
Pardo-Reoyo S, Roig-Lopez JL, Yang ES. Potential biomarkers for radiosensitivity in head and neck cancers. Annals of Translational Medicine. 4: 524. PMID 28149885 DOI: 10.21037/Atm.2016.12.45 |
0.366 |
|
| 2016 |
Wielgos ME, Rajbhandari R, Cooper TS, Wei S, Nozell SE, Yang ES. Let-7 Status is Crucial for PARP1 Expression in HER2-overexpressing Breast Tumors. Molecular Cancer Research : McR. PMID 28031413 DOI: 10.1158/1541-7786.Mcr-16-0287-T |
0.335 |
|
| 2016 |
Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. PMID 27888804 DOI: 10.18632/Oncotarget.13466 |
0.398 |
|
| 2016 |
Dulaney C, Rais-Bahrami S, Della Manna D, Gordetsky J, Nix J, Yang ES. Clinical and Radiographic Correlates of Canonical Cancer Pathway Deregulation in Malignant Intraprostatic Lesions. International Journal of Radiation Oncology, Biology, Physics. 96: E251. PMID 27674179 DOI: 10.1016/J.Ijrobp.2016.06.1253 |
0.312 |
|
| 2016 |
McDonald AM, Swain TA, Mayhew DL, Cardan RA, Baker CB, Harris DM, Yang ES, Fiveash JB. CT Measures of Bone Mineral Density and Muscle Mass Can Be Used to Predict Noncancer Death in Men with Prostate Cancer. Radiology. 160626. PMID 27598538 DOI: 10.1148/Radiol.2016160626 |
0.301 |
|
| 2016 |
Ghatalia P, Yang ES, Lasseigne BN, Ramaker RC, Cooper SJ, Chen D, Sudarshan S, Wei S, Guru AS, Zhao A, Cooper T, Della Manna DL, Naik G, Myers RM, Sonpavde G. Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. Plos One. 11: e0160924. PMID 27574806 DOI: 10.1371/Journal.Pone.0160924 |
0.36 |
|
| 2016 |
Weaver AN, Burch MB, Cooper TS, Della Manna DL, Wei S, Ojesina AI, Rosenthal EL, Yang ES. Notch Signaling Activation is Associated with Patient Mortality and Increased FGF1-mediated Invasion in Squamous Cell Carcinoma of the Oral Cavity. Molecular Cancer Research : McR. PMID 27353029 DOI: 10.1158/1541-7786.Mcr-16-0114 |
0.385 |
|
| 2016 |
McNally LR, Mezera M, Morgan DE, Frederick PJ, Yang ES, Eltoum IE, Grizzle WE. Current and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in Oncology. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27208064 DOI: 10.1158/1078-0432.Ccr-16-0573 |
0.311 |
|
| 2016 |
Baker CB, McDonald AM, Yang ES, Jacob R, Rais-Bahrami S, Nix JW, Fiveash JB. Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma. Prostate Cancer. 2016: 2674954. PMID 27051534 DOI: 10.1155/2016/2674954 |
0.3 |
|
| 2016 |
Dulaney CR, Osula DO, Yang ES, Rais-Bahrami S. Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer. 2016: 4897515. PMID 27022486 DOI: 10.1155/2016/4897515 |
0.353 |
|
| 2016 |
Dobbin ZC, Landers EE, Londono AI, Katre AA, Yang ES, Boone JD, Bevis KS, Straughn JM, Huh WK, Leath CA, Crossman D, Alvarez RD, Arend RC. Genomic profiling of high-intermediate risk endometrial cancer to differentiate recurrence risk. Journal of Clinical Oncology. 34: e17103-e17103. DOI: 10.1200/Jco.2016.34.15_Suppl.E17103 |
0.303 |
|
| 2016 |
Miller AL, Garcia PL, Gamblin TL, Cui X, Bradner JE, Yang ES, Yoon KJ. Abstract 1293: JQ1 sensitivity of patient-derived xenograft models of cholangiocarcinoma Cancer Research. 76: 1293-1293. DOI: 10.1158/1538-7445.Am2016-1293 |
0.411 |
|
| 2016 |
Yang E, William W, Fayette J, Zhang W, Fink A, Lin AB, Deutsch E. Phase 1b trial of LY2606368 in combination with chemoradiation in patients with locally advanced head and neck squamous cell cancer Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw376.71 |
0.343 |
|
| 2015 |
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, ... ... Yang ES, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology. 35: S276-304. PMID 26590477 DOI: 10.1016/J.Semcancer.2015.09.007 |
0.369 |
|
| 2015 |
Bonner JA, Trummell HQ, Bonner AB, Willey CD, Bredel M, Yang ES. Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition. Bmc Cancer. 15: 673. PMID 26458879 DOI: 10.1186/S12885-015-1679-X |
0.305 |
|
| 2015 |
Weaver AN, Cooper TS, Rodriguez M, Trummell HQ, Bonner JA, Rosenthal EL, Yang ES. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma. Oncotarget. 6: 26995-7007. PMID 26336991 DOI: 10.18632/Oncotarget.4863 |
0.336 |
|
| 2015 |
Garcia PL, Miller AL, Kreitzburg KM, Council LN, Gamblin TL, Christein JD, Heslin MJ, Arnoletti JP, Richardson JH, Chen D, Hanna CA, Cramer SL, Yang ES, Qi J, Bradner JE, et al. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene. PMID 25961927 DOI: 10.1038/Onc.2015.126 |
0.354 |
|
| 2015 |
Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, Malhotra M, Meeker AK, Amedei A, Amin A, Ashraf SS, Aquilano K, Azmi AS, Bhakta D, Bilsland A, ... ... Yang ES, et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology. PMID 25869442 DOI: 10.1016/J.Semcancer.2015.03.005 |
0.378 |
|
| 2015 |
Stanley J, Klepczyk L, Keene K, Wei S, Li Y, Forero A, Grizzle W, Wielgos M, Brazelton J, LoBuglio AF, Yang ES. PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Research and Treatment. 150: 569-79. PMID 25833211 DOI: 10.1007/S10549-015-3359-6 |
0.373 |
|
| 2015 |
Rohrbach TD, Jarboe JS, Anderson JC, Trummell HQ, Hicks PH, Weaver AN, Yang ES, Oster RA, Deshane JS, Steele C, Siegal GP, Bonner JA, Willey CD. Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity. International Journal of Oncology. 46: 1079-88. PMID 25524703 DOI: 10.3892/Ijo.2014.2799 |
0.411 |
|
| 2015 |
Isayeva T, Xu J, Ragin C, Dai Q, Cooper T, Carroll W, Dayan D, Vered M, Wenig B, Rosenthal E, Grizzle W, Anderson J, Willey CD, Yang ES, Brandwein-Gensler M. The protective effect of p16(INK4a) in oral cavity carcinomas: p16(Ink4A) dampens tumor invasion-integrated analysis of expression and kinomics pathways. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28: 631-53. PMID 25523612 DOI: 10.1038/Modpathol.2014.149 |
0.333 |
|
| 2015 |
Ghatalia P, Yang ES, Chen D, Wei S, Cooper T, Sudarshan S, Naik G, Sonpavde G. Kinase gene expression profiling of metastatic tumor tissue to prioritize therapeutic targets in clear cell renal cell carcinoma. Journal of Clinical Oncology. 33: 476-476. DOI: 10.1200/Jco.2015.33.7_Suppl.476 |
0.341 |
|
| 2015 |
Mehta AN, Yang ES, Willey CD, Crowley M, Chen D, Anderson J, Naik G, Cooper T, Sonpavde G. Multiplatform comprehensive kinase analysis of penile squamous cell carcinoma (PSCC) to identify drivers and potentially actionable therapeutic targets. Journal of Clinical Oncology. 33: 389-389. DOI: 10.1200/Jco.2015.33.7_Suppl.389 |
0.361 |
|
| 2015 |
Baker C, McDonald AM, Clark G, Dulaney C, Yang ES, Jacob R, Fiveash JB. Treatment outcomes of radiotherapy versus prostatectomy for localized prostate cancer with Gleason 8 or more on biopsy. Journal of Clinical Oncology. 33: 120-120. DOI: 10.1200/Jco.2015.33.7_Suppl.120 |
0.355 |
|
| 2015 |
Mehta AN, Yang ES, Necchi A, Giannatempo P, Colecchia M, Eigl BJ, Chen D, Bae S, Naik G, Gordetsky J, Wei S, Cooper T, Sonpavde G. Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy. Journal of Clinical Oncology. 33: e15633-e15633. DOI: 10.1200/Jco.2015.33.15_Suppl.E15633 |
0.352 |
|
| 2015 |
Wielgos M, Cooper T, Forero-Torres A, Esteva FJ, Schiff R, Osborne CK, LoBuglio AF, Yang ES. Crosstalk between PARP-1 and NF-κB signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines. Journal of Clinical Oncology. 33: 606-606. DOI: 10.1200/Jco.2015.33.15_Suppl.606 |
0.408 |
|
| 2015 |
Stanley JA, Klepczyk LC, Keene KS, Wei S, Li Y, Forero-Torres A, Grizzle WE, Wielgos M, Brazelton JD, LoBuglio AF, Yang ES. Expression levels of PARP1 and phospho-p65 protein in human HER2-positive breast cancers. Journal of Clinical Oncology. 33: 601-601. DOI: 10.1200/Jco.2015.33.15_Suppl.601 |
0.376 |
|
| 2015 |
Bredel M, Ferrarese R, Thudi NK, Puliyappadamba VK, Bug E, Trummell H, Anderson J, Willey CD, Yang ES, Beck W, Bonner JA, Carro M. Targeting PTBP1 as a therapeutic strategy to reverse lineage-specific splicing of ANXA7 and ensuing EGFR activation in glioblastoma. Journal of Clinical Oncology. 33: 2075-2075. DOI: 10.1200/Jco.2015.33.15_Suppl.2075 |
0.307 |
|
| 2015 |
Zhao A, Guru A, Guru S, Yang E, Li Y. Gene expression in primary and metastatic kidney cancer to discover drivers of metastasis and targets for drug development Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P215 |
0.343 |
|
| 2015 |
Weaver AN, Cooper TS, Trummell HQ, Bonner JA, Rosenthal EL, Yang ES. Abstract A1-63: Characterizing the DNA damage repair defect in HPV-positive oropharyngeal squamous cell carcinoma Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-63 |
0.366 |
|
| 2015 |
Garcia PL, Miller AL, Kreitzburg K, Gamblin TL, Christein JD, Arnoletti P, Heslin M, Reddy S, Richardson JH, Yang ES, Qi J, Bradner JE, Yoon KJ. Abstract 1779: Bromodomain inhibitor JQ1 inhibits cholangiocarcinoma tumor growth in patient-derived xenograft models Cancer Research. 75: 1779-1779. DOI: 10.1158/1538-7445.Am2015-1779 |
0.375 |
|
| 2015 |
Wielgos ME, Rajbhandari R, Nozell S, Osborne CK, Schiff R, Yang ES. Abstract A62: PARP-1 regulates NF-κB-mediated IL-8 expression in HER2 positive breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A62 |
0.383 |
|
| 2014 |
McDonald AM, Baker CB, Shekar K, Popple RA, Clark GM, Yang ES, Jacob R, Kim RY, Fiveash JB. Reduced radiation tolerance of penile structures associated with dose-escalated hypofractionated prostate radiotherapy. Urology. 84: 1383-7. PMID 25440987 DOI: 10.1016/J.Urology.2014.07.060 |
0.316 |
|
| 2014 |
McDonald AM, Baker CB, Popple RA, Shekar K, Yang ES, Jacob R, Cardan R, Kim RY, Fiveash JB. Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy. Radiation Oncology (London, England). 9: 129. PMID 24893842 DOI: 10.1186/1748-717X-9-129 |
0.323 |
|
| 2014 |
Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecologic Oncology. 134: 331-7. PMID 24844596 DOI: 10.1016/J.Ygyno.2014.05.009 |
0.41 |
|
| 2014 |
Jian W, Xu HG, Chen J, Xu ZX, Levitt JM, Stanley JA, Yang ES, Lerner SP, Sonpavde G. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anti-Cancer Drugs. 25: 878-86. PMID 24714082 DOI: 10.1097/Cad.0000000000000114 |
0.328 |
|
| 2014 |
McDonald AM, Jacob R, Yang ES, Dobelbower MC, Vanlandingham S, Fiveash JB. PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalation Urologic Oncology: Seminars and Original Investigations. 32: 687-693. PMID 24656630 DOI: 10.1016/J.Urolonc.2013.10.019 |
0.371 |
|
| 2014 |
Nowsheen S, Aziz K, Tran PT, Gorgoulis VG, Yang ES, Georgakilas AG. Epigenetic inactivation of DNA repair in breast cancer. Cancer Letters. 342: 213-22. PMID 22634493 DOI: 10.1016/J.Canlet.2012.05.015 |
0.383 |
|
| 2014 |
Whitley A, Cooper T, Angajala A, Trummell H, Jackson J, Bonner JA, Yang ES. Radiosensitization by erlotinib and veliparib in esophageal squamous cell cancer. Journal of Clinical Oncology. 32: 70-70. DOI: 10.1200/Jco.2014.32.3_Suppl.70 |
0.452 |
|
| 2014 |
Stanley JA, Nowsheen S, Cooper T, Forero A, LoBuglio A, Yang E. Abstract 5471: Contextual synthetic lethality in human triple negative breast cancer cells involving a novel interaction between DNA repair proteins EGFR, PARP1, and BRCA1 Cancer Research. 74: 5471-5471. DOI: 10.1158/1538-7445.Am2014-5471 |
0.39 |
|
| 2014 |
Wielgos ME, Cooper T, Forero A, Bonner JA, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Yang ES. Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition Cancer Research. 74: 5469-5469. DOI: 10.1158/1538-7445.Am2014-5469 |
0.414 |
|
| 2014 |
Thompson J, Keene K, Hinton B, De Los Santos J, Yang E, Forero-Torres A, Tuomela J, Desmond R, Vuopala K, Vaklavas C, Selander K. Toll-Like Receptor-9 Expression Does not Predict for Breast Cancer Specific Outcome in African-American Triple-Negative Breast Cancer Patients International Journal of Radiation Oncology*Biology*Physics. 90: S815. DOI: 10.1016/J.Ijrobp.2014.05.2349 |
0.317 |
|
| 2013 |
McDonald AM, Bae S, Singh KP, Jacob R, Dobelbower MC, Kim RY, Yang ES, Fiveash JB. Patient benefit from salvage radiation for prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 175. PMID 28136790 DOI: 10.1200/Jco.2013.31.6_Suppl.175 |
0.365 |
|
| 2013 |
Weaver AN, Yang ES. Beyond DNA Repair: Additional Functions of PARP-1 in Cancer. Frontiers in Oncology. 3: 290. PMID 24350055 DOI: 10.3389/Fonc.2013.00290 |
0.412 |
|
| 2013 |
Wielgos M, Yang ES. Discussion of PARP inhibitors in cancer therapy. Pharmaceutical Patent Analyst. 2: 755-66. PMID 24237241 DOI: 10.4155/Ppa.13.53 |
0.417 |
|
| 2013 |
Swindall AF, Stanley JA, Yang ES. PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis? Cancers. 5: 943-58. PMID 24202328 DOI: 10.3390/Cancers5030943 |
0.344 |
|
| 2013 |
Jiang G, Plo I, Wang T, Rahman M, Cho JH, Yang E, Lopez BS, Xia F. BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal double-strand breaks in the G1 phase of the cell cycle. The Journal of Biological Chemistry. 288: 8966-76. PMID 23344954 DOI: 10.1074/Jbc.M112.412650 |
0.307 |
|
| 2013 |
Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 170-82. PMID 23147994 DOI: 10.1158/1078-0432.Ccr-12-1045 |
0.456 |
|
| 2013 |
Gebhardt BJ, McDonald AM, Bae S, Singh KP, Jacob R, Dobelbower MC, Yang ES, Fiveash JB. Prognostic factors for salvage radiotherapy with an analysis of post-prostatectomy PSA kinetics Journal of Solid Tumors. 3. DOI: 10.5430/Jst.V3N4P32 |
0.336 |
|
| 2013 |
Klepczyk LC, Wei S, Brazelton JD, Keene KS, Bonner JA, LoBuglio AF, Forero A, Grizzle WE, Yang ES. Correlation between poly (ADP-ribose) polymerase (PARP) and phospho-p65 expression in human breast cancer. Journal of Clinical Oncology. 31: 623-623. DOI: 10.1200/Jco.2013.31.15_Suppl.623 |
0.42 |
|
| 2013 |
Cooper T, Rodriguez M, Trummell HQ, Weaver A, Bonner JA, Yang ES. Abstract 635: PARP inhibition in HPV positive head and neck cancers. Cancer Research. 73: 635-635. DOI: 10.1158/1538-7445.Am2013-635 |
0.347 |
|
| 2013 |
Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Sood AK, Conner MG, Yang ES, Landen CN. Abstract 5475: Endoglin (CD105) is a target for ovarian cancer cell-specific therapy through induction of DNA damage. Cancer Research. 73: 5475-5475. DOI: 10.1158/1538-7445.Am2013-5475 |
0.45 |
|
| 2013 |
Klepczyk L, Wei S, Brazelton J, Keene K, Li Y, Bonner J, Forero A, LoBuglio A, Grizzle W, Yang E. Abstract B37: Increased expression of poly (ADP-ribose) polymerase (PARP) and phospho-p65 in human HER2+ breast cancer Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-B37 |
0.424 |
|
| 2013 |
Shah M, Nowsheen S, Katre A, Dobbin Z, Erickson B, Alvarez R, Konstantinopoulos P, Yang E, Landen C. Towards personalized PARP therapy: XRT-induced Rad51 predicts re- sponse to ABT-888 in ovarian cancer Gynecologic Oncology. 130: e35. DOI: 10.1016/J.Ygyno.2013.04.142 |
0.342 |
|
| 2012 |
Nowsheen S, Xia F, Yang ES. Assaying DNA damage in hippocampal neurons using the comet assay. Journal of Visualized Experiments : Jove. e50049. PMID 23271144 DOI: 10.3791/50049 |
0.303 |
|
| 2012 |
Nowsheen S, Cooper T, Stanley JA, Yang ES. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. Plos One. 7: e46614. PMID 23071597 DOI: 10.1371/Journal.Pone.0046614 |
0.396 |
|
| 2012 |
Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Research. 72: 4796-806. PMID 22987487 DOI: 10.1158/0008-5472.Can-12-1287 |
0.421 |
|
| 2012 |
McDonald AM, Bishop JM, Jacob R, Dobelbower MC, Kim RY, Yang ES, Smith H, Wu X, Fiveash JB. Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry. Prostate Cancer. 2012: 546794. PMID 22966463 DOI: 10.1155/2012/546794 |
0.343 |
|
| 2012 |
Yang ES, Nowsheen S, Rahman MA, Cook RS, Xia F. Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Research. 72: 5547-55. PMID 22962264 DOI: 10.1158/0008-5472.Can-12-0934 |
0.395 |
|
| 2012 |
Jarboe JS, Jaboin JJ, Anderson JC, Nowsheen S, Stanley JA, Naji F, Ruijtenbeek R, Tu T, Hallahan DE, Yang ES, Bonner JA, Willey CD. Kinomic profiling approach identifies Trk as a novel radiation modulator. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 103: 380-7. PMID 22561027 DOI: 10.1016/J.Radonc.2012.03.014 |
0.329 |
|
| 2012 |
Nowsheen S, Whitley AC, Yang ES. Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy. Current Molecular Medicine. 12: 788-803. PMID 22292444 DOI: 10.2174/156652412800792615 |
0.395 |
|
| 2012 |
Yang ES, Nowsheen S, Cooper T, LoBuglio AF, Bonner JA. Susceptibility of HER2+ breast cancer cells to poly (ADP-ribose) polymerase (PARP) inhibition independent of an inherent DNA repair defect. Journal of Clinical Oncology. 30: 621-621. DOI: 10.1200/Jco.2012.30.15_Suppl.621 |
0.438 |
|
| 2012 |
Whitley A, Nowsheen S, Cooper T, LoBuglio A, Bonner J, Yang ES. Abstract 4684: Synthetic lethal interaction between EGFR and PARP inhibition Cancer Research. 72: 4684-4684. DOI: 10.1158/1538-7445.Am2012-4684 |
0.445 |
|
| 2012 |
Yang E, Nowsheen S, Cooper T, Landen C, Bonner J. Poly (ADP-Ribose) polymerase inhibition attenuates radiation-induced non-homologous end-joining repair and augments cervical cancer response to radiation Gynecologic Oncology. 125: S54-S55. DOI: 10.1016/J.Ygyno.2011.12.130 |
0.35 |
|
| 2012 |
Nowsheen S, Cooper T, LoBuglio A, Bonner J, Yang E. Synthetic Lethal Interactions Between EGFR and PARP Inhibition in Triple Negative Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S176-S177. DOI: 10.1016/J.Ijrobp.2012.07.457 |
0.346 |
|
| 2012 |
Whitley A, Jackson J, Trummell H, Bonner J, Yang E. Erlotinib Induces Synthetic Lethality With the Poly(ADP-Ribose) Polymerase (PARP) Inhibitor ABT-888 in Esophageal Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S165-S166. DOI: 10.1016/J.Ijrobp.2012.07.428 |
0.383 |
|
| 2012 |
Bonner J, Trummell H, Nowsheen S, Yang E. The Role of STAT-3 in Cetuximab-induced Radiosensitization in Head-and-Neck Cancer Cells International Journal of Radiation Oncology*Biology*Physics. 84: S165. DOI: 10.1016/J.Ijrobp.2012.07.426 |
0.382 |
|
| 2012 |
Yang E, Nowsheen S, Cooper T, Bonner J, LoBuglio A. Human HER2+ Breast Cancer Susceptibility to Poly(ADP-Ribose) Polymerase Inhibitors Independent of a Homologous Recombination Repair Defect International Journal of Radiation Oncology*Biology*Physics. 84: S73-S74. DOI: 10.1016/J.Ijrobp.2012.07.296 |
0.357 |
|
| 2011 |
Mills CN, Nowsheen S, Bonner JA, Yang ES. Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Frontiers in Molecular Neuroscience. 4: 47. PMID 22275880 DOI: 10.3389/Fnmol.2011.00047 |
0.394 |
|
| 2011 |
Nowsheen S, Bonner JA, Lobuglio AF, Trummell H, Whitley AC, Dobelbower MC, Yang ES. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. Plos One. 6: e24148. PMID 21912620 DOI: 10.1371/Journal.Pone.0024148 |
0.44 |
|
| 2011 |
Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, Haffty B, Xia F. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Research. 71: 5546-57. PMID 21742769 DOI: 10.1158/0008-5472.Can-10-3423 |
0.398 |
|
| 2011 |
Bonner JA, Willey CD, Yang ES, Dobelbower MC, Sanford LL, Bright SJ, Buchsbaum DJ, Raisch KP. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 101: 183-9. PMID 21722984 DOI: 10.1016/J.Radonc.2011.05.083 |
0.357 |
|
| 2011 |
Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 99: 331-8. PMID 21719137 DOI: 10.1016/J.Radonc.2011.05.084 |
0.457 |
|
| 2011 |
Bonner JA, Yang ES, Trummell HQ, Nowsheen S, Willey CD, Raisch KP. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 99: 339-43. PMID 21704410 DOI: 10.1016/J.Radonc.2011.05.070 |
0.377 |
|
| 2011 |
Yang ES, Nowsheen S, Wang T, Thotala DK, Xia F. Glycogen synthase kinase 3beta inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons. Neuro-Oncology. 13: 459-70. PMID 21398658 DOI: 10.1093/Neuonc/Nor016 |
0.344 |
|
| 2011 |
Whitley AC, Nowsheen S, Trummell H, LoBuglio A, Bonner JA, Yang ES. Abstract 5496: Cetuximab induces synthetic lethality with the poly (ADP-Ribose) polymerase (PARP) inhibitor ABT-888 in head and neck cancer Cancer Research. 71: 5496-5496. DOI: 10.1158/1538-7445.Am2011-5496 |
0.467 |
|
| 2011 |
Fiveash J, Bishop J, Jacob R, Kim R, Dobelbower M, Yang E, McDonald A, Smith H, Wu X. Daily Rectal Dosimetry in Patients with Late Grade 2 or Greater Rectal Toxicity After Hypofractionated Image Guided Radiation Therapy for Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 81: S447. DOI: 10.1016/J.Ijrobp.2011.06.744 |
0.372 |
|
| 2011 |
Yang E, Nowsheen S. Targeting HER Pathways to Render Breast Cancer Cells Susceptible to Poly (ADP-ribose) Polymerase (PARP) Inhibition International Journal of Radiation Oncology*Biology*Physics. 81: S738. DOI: 10.1016/J.Ijrobp.2011.06.1219 |
0.382 |
|
| 2011 |
Klepczyk L, Nowsheen S, Xia F, Yang E. BRCA1 Nuclear Export Sensitizes Prostate Cancer Cells to Poly (ADP-ribose) Polymerase (PARP) Inhibition via the CRM1/exportin Pathway International Journal of Radiation Oncology*Biology*Physics. 81: S24-S25. DOI: 10.1016/J.Ijrobp.2011.06.050 |
0.405 |
|
| 2010 |
Wang H, Yang ES, Jiang J, Nowsheen S, Xia F. DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Research. 70: 6258-67. PMID 20631074 DOI: 10.1158/0008-5472.Can-09-4713 |
0.375 |
|
| 2010 |
Yang ES, Xia F. BRCA1 16 years later: DNA damage-induced BRCA1 shuttling. The Febs Journal. 277: 3079-85. PMID 20608971 DOI: 10.1111/J.1742-4658.2010.07734.X |
0.369 |
|
| 2010 |
Pawlowski JM, Yang ES, Malcolm AW, Coffey CW, Ding GX. Reduction of Dose Delivered to Organs at Risk in Prostate Cancer Patients via Image-Guided Radiation Therapy International Journal of Radiation Oncology Biology Physics. 76: 924-934. PMID 20004528 DOI: 10.1016/J.Ijrobp.2009.06.068 |
0.341 |
|
| 2009 |
Wu FY, Yang ES, Willey CD, Ely K, Garrett G, Cmelak AJ. Refractory lympho-epithelial carcinoma of the nasopharynx: a case report illustrating a protracted clinical course. Head & Neck Oncology. 1: 18. PMID 19527509 DOI: 10.1186/1758-3284-1-18 |
0.332 |
|
| 2009 |
Yang ES, Wang H, Jiang G, Nowsheen S, Fu A, Hallahan DE, Xia F. Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. The Journal of Clinical Investigation. 119: 1124-35. PMID 19425167 DOI: 10.1172/Jci34051 |
0.347 |
|
| 2009 |
Yang ES, Murphy BM, Chung CH, Netterville JL, Burkey BB, Gilbert J, Yarbrough WG, Sinard R, Cmelak AJ. Evolution of clinical trials in head and neck cancer. Critical Reviews in Oncology/Hematology. 71: 29-42. PMID 18996026 DOI: 10.1016/J.Critrevonc.2008.09.015 |
0.373 |
|
| 2009 |
Pawlowski J, Yang E, Malcolm A, Coffey C, Ding G. SU-FF-J-92: A Dosimetric Study of the Potential for Margin Reduction in Prostate IMRT Using Image-Guided Target Localization Medical Physics. 36: 2497-2497. DOI: 10.1118/1.3181384 |
0.312 |
|
| 2009 |
Nowsheen S, Yang E, Hallahan D, Xia F. Inhibition of GSK3β Enhances Repair of Radiation-induced DNA Double Strand Breaks in Hippocampal Neurons International Journal of Radiation Oncology*Biology*Physics. 75: S550. DOI: 10.1016/J.Ijrobp.2009.07.1257 |
0.307 |
|
| 2008 |
Li L, Wang H, Yang ES, Arteaga CL, Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Research. 68: 9141-6. PMID 19010885 DOI: 10.1158/0008-5472.Can-08-1127 |
0.44 |
|
| 2008 |
Pawlowski J, Ding G, Coffey C, Yang E, Malcolm A. SU-GG-J-148: Planned Target Dose Vs. Delivered Target Dose for Prostate IMRT Treatment Medical Physics. 35: 2713-2713. DOI: 10.1118/1.2961697 |
0.303 |
|
| 2008 |
Yang E, Wang H, Li L, Xia F. Dissociation of BRCA1's DNA Repair Function from DNA Damage-induced Cytotoxicity: A Dependence on BRCA1 Subcellular Localization International Journal of Radiation Oncology*Biology*Physics. 72: S69. DOI: 10.1016/J.Ijrobp.2008.06.923 |
0.308 |
|
| 2007 |
Jaboin JJ, Shinohara ET, Moretti L, Yang ES, Kaminski JM, Lu B. The role of mTOR inhibition in augmenting radiation induced autophagy. Technology in Cancer Research & Treatment. 6: 443-7. PMID 17877432 DOI: 10.1177/153303460700600510 |
0.396 |
|
| 2007 |
Moretti L, Yang ES, Kim KW, Lu B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 10: 135-43. PMID 17627865 DOI: 10.1016/J.Drup.2007.05.001 |
0.379 |
|
| 2004 |
Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, Burnstein KL. Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene. 23: 5513-22. PMID 15077174 DOI: 10.1038/Sj.Onc.1207708 |
0.663 |
|
| 2003 |
Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. The Journal of Biological Chemistry. 278: 46862-8. PMID 12954644 DOI: 10.1074/Jbc.M306340200 |
0.617 |
|
| 2002 |
Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Molecular and Cellular Endocrinology. 186: 69-79. PMID 11850123 DOI: 10.1016/S0303-7207(01)00671-2 |
0.644 |
|
| Show low-probability matches. |